Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation

Prolonged exposure to temozolomide (TMZ) could improve clinical outcomes in recurrent glioblastoma multiforme (GBM) patients. We previously developed a dose-dense regimen of TMZ in a phase II study (180 mg/m(2) from days 1 to 5 every two weeks). A retrospective analysis of patients with macroscopic...

Descripción completa

Detalles Bibliográficos
Autores principales: Napoleoni, Luca, Cortellini, Alessio, Cannita, Katia, Parisi, Alessandro, Dal Mas, Antonella, Calvisi, Giuseppe, Venditti, Olga, Lanfiuti Baldi, Paola, Cocciolone, Valentina, Ricci, Alessandro, Ficorella, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466220/
https://www.ncbi.nlm.nih.gov/pubmed/30678211
http://dx.doi.org/10.3390/bioengineering6010011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466220/
https://www.ncbi.nlm.nih.gov/pubmed/30678211
http://dx.doi.org/10.3390/bioengineering6010011

Ejemplares similares